A Vaccine Study for High Risk Cancers

NCT ID: NCT00944580

Last Updated: 2017-11-24

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-06-30
• Study Completion Date: 2010-08-31

Brief Summary

The purpose of this study is to determine the safety and immunological effects of a vaccine for people diagnosed with high risk neuroblastoma, osteogenic sarcoma, and rhabdomyosarcoma. It is hypothesized that this vaccine could reduce the incidence of relapse.

Detailed Description

MAGE -A1, MAGE- A3, and NY-ESO-1 are antigens that can be found with significant frequency on neuroblastoma, rhabdomyosarcoma, and osteogenic sarcoma, three relatively common solid tumors that in some cases can be associated with a high risk for relapse. In this study each subject will be screened for the presence of these antigens, and an individualized vaccine will be developed and administered using the subject's own dendritic cells (DC).

This study consists of two phases: a screening phase and a treatment/vaccine phase. First, eligible individuals will be consented into the screening phase. Tumor specimens will be tested by immunohistochemistry or RT-PCR for the presence of MAGE- A1, MAGE- A3, and NY-ESO-1. Those testing positive for one or more antigen can be consented for the treatment phase of the study. Blood will be drawn for DC culture, and approximately one month later a series of three vaccines will be administered at two week intervals. Subjects will receive a topical medication called imiquimod to the vaccine site prior to and following each injection, to help immune cells travel into the area. Study participation occurs over 18 months and also involves periodic physical examinations and blood draws.

Conditions

Neuroblastoma; Rhabdomyosarcoma; Osteogenic Sarcoma

Keywords

MAGE-A1; MAGE-A3; NY-ESO-1; antigen; vaccine; dendritic cells; immunohistochemistry; immunology

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Vaccine Intervention

MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine: A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.

Group Type: EXPERIMENTAL

MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine

Intervention Type: BIOLOGICAL

A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.

Interventions

MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine

A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

Patient 1 to 70 years of age with neuroblastoma, rhabdomyosarcoma, or osteogenic sarcoma, who have one or more of the following high risk features:

• Neuroblastoma:

• Stage IV disease
• Stage III disease with n-myc amplification
• Osteogenic sarcoma:

• Presence of metastases
• Elevated alkaline phosphatase or LDH at diagnosis
• Primary tumor affecting the axial skeleton
• Poor histopathological response after completion of pre-surgical chemotherapy (≥10% viable tumor)
• Rhabdomyosarcoma:

• Stage IV disease
• Alveolar histology
• Positive tumor margins, with lymph node positivity

• Patient meets all screening criteria and tumor is positive for NY-ESO-1, MAGE- A1, or MAGE-A3 by immunohistochemistry or RT-PCR.
• Patients who are between 3 months and 2 years following the completion of therapy, and have achieved at least a very good partial response to primary therapy.
• No chemotherapy is planned for one month following the last vaccination.
• Bilirubin <2 mg/dL, and SGOT/SGPT <2.5 x normal
• Creatinine clearance > 50ml/min as estimated by patient's serum creatinine, weight, and age
• Room air pulse oximetry >94%
• Patient is not pregnant
• Male and female sexually active patients of reproductive who wish to participate must agree to use acceptable contraception
• Patient is not moribund and has a projected life expectancy >6 months
• Lansky performance scale > 70, ECOG < 2 (Appendix I)
• Potential subjects will be tested for HIV 1 and 2 antibodies, HTLV 1/2 antibodies, and for HIV 1, hepatitis C and hepatitis B virus by NAT testing. - -Subjects testing positive for any of these pathogens will be ineligible for vaccine.
• White blood cells ≥ 2.5 K/µL, Hemoglobin ≥ 8 g/dL, Hematocrit > 25%, and Platelets ≥ 70 K/µL
• Patient does not have central nervous system involvement.
• Patient does not a have a history of autoimmune disease, specifically inflammatory bowel disease, systemic lupus erythematosis, or rheumatoid arthritis
• Patient is not receiving concurrent systemic steroid therapy
• Patient does not have a known systemic hypersensitivity to imiquimod or any vaccine component

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Penn State University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kenneth G. Lucas, MD

Role: STUDY_CHAIR

Milton S. Hershey Medical Center

Countries

United States

Other Identifiers

PSHCI 09-033

Identifier Type: -

Identifier Source: secondary_id

IRB 30761

Identifier Type: -

Identifier Source: org_study_id